"""
Question: 1101

Evidence: This study was funded by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS), and PROPPEX-FEEVALE and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) —Finance Code 001. To the best of our knowledge, this is the first study to evaluate TDRMs against INSTIs in Brazil.

Rationale: The paper explicitly states that this is the first study to evaluate transmitted drug resistance mutations (TDRMs) against integrase strand transfer inhibitors (INSTIs) in Brazil, indicating it contains previously unpublished data. The funding sources and original research methodology further confirm this is a new study reporting original findings.

Answer: Yes
"""

"""
Question: 1102

Evidence: Viral RNA from 42 ART-naive individuals was submitted to complete HIV-1 integrase gene amplifica- tion by RT–PCR and sequencing. The complete integrase gene was amplified using two different nested PCR protocols. Sequence editing and de novo assembly were performed using the Geneious Prime 2022.1 bioinformatics suite.

Rationale: The paper describes in detail the methods used for HIV sequencing, including RNA extraction, RT-PCR amplification of the complete integrase gene, and sequence assembly. This clearly indicates that HIV sequences were generated and analyzed in this study.

Answer: Yes
"""

"""
Question: 1103

Evidence: The paper does not mention any in vitro passage experiments. The study focuses on sequencing viral samples from ART-naive individuals and analyzing genetic diversity and drug resistance mutations.

Rationale: After thoroughly reviewing the paper content, no references to in vitro passage experiments were found. The research methodology involves sequencing clinical samples from patients, not laboratory passage experiments.

Answer: No
"""

"""
Question: 1104

Evidence: All the volunteers were susceptible to INSTIs when submitted to the Stanford University HIV Drug Resistance Database algorithm. Moreover, none of the 42 individuals presented major mutations against raltegravir, dolutegravir, elvitegravir, bictegravir or cabotegravir.

Rationale: The paper reports drug susceptibility data, but it is based on genotypic analysis using the Stanford HIV Drug Resistance Database algorithm, not on in vitro phenotypic susceptibility testing. The susceptibility conclusions are derived from mutation analysis rather than laboratory IC50 measurements.

Answer: No
"""

"""
Question: 2101

Evidence: The paper does not mention any GenBank accession numbers. The methods section describes sequencing and analysis but does not reference deposition of sequences in GenBank.

Rationale: After careful review of the entire paper content, no GenBank accession numbers are mentioned for any HIV sequences, including laboratory isolates.

Answer: No
"""

"""
Question: 2102

Evidence: The paper does not mention any GenBank accession numbers. The sequences were analyzed using various bioinformatics tools but were not deposited in GenBank according to the text.

Rationale: The paper contains no references to GenBank accession numbers for any type of HIV sequences, whether from clinical isolates or laboratory strains.

Answer: No
"""

"""
Question: 2103

Evidence: The paper does not mention any GenBank accession numbers. The sequences were analyzed using various bioinformatics tools but were not deposited in GenBank according to the text.

Rationale: No GenBank accession numbers are reported anywhere in the paper. The sequences were analyzed locally using bioinformatics suites but not submitted to public databases.

Answer: NA
"""

"""
Question: 2202

Evidence: However, the poly- morphisms L74M and L74I were each observed in 4.8% of the individuals. The TDRM analysis was performed using the Stanford University HIV Drug Resistance Database algorithm.

Rationale: While the paper mentions specific polymorphisms (L74M and L74I) found in some individuals, it does not provide comprehensive lists of mutations for individual sequenced HIV isolates. Only specific mutations of interest are reported in aggregate.

Answer: No
"""

"""
Question: 2301

Evidence: The HIV-1 genetic diversity and the presence of transmitted drug resistance mutations (TDRMs) against integrase strand transfer inhibitors (INSTIs) were assessed sequencing samples of antiretroviral (ARV)-naive HIV-1-infected individuals from South Brazil.

Rationale: The paper explicitly states that it studied HIV-1, which is the only HIV species mentioned throughout the text. No references to HIV-2 or other HIV species are made.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: When submitted to HIV-1 subtyping, 50% were classified as subtype C, 21% as recombinant BC, 19% as subtype B, 4.8% as subtype F1 and 4.8% as recombinant CF1.

Rationale: The paper provides detailed subtype distribution results from the 42 samples analyzed, showing the prevalence of subtype C, recombinant BC, subtype B, subtype F1, and recombinant CF1.

Answer: Subtype C, recombinant BC, subtype B, subtype F1, recombinant CF1
"""

"""
Question: 2303

Evidence: Viral RNA from 42 ART-naive individuals was submitted to complete HIV-1 integrase gene amplifica- tion by RT–PCR and sequencing. The complete integrase gene was amplified using two different nested PCR protocols.

Rationale: The paper specifically states that only the complete integrase gene was sequenced in this study. No other HIV genes (such as protease or reverse transcriptase) were sequenced.

Answer: Integrase gene
"""

"""
Question: 2304

Evidence: The complete integrase gene was amplified using two different nested PCR protocols. In the present work, TDRMs against INSTIs were also evaluated in the 42 ARV-naive recently diagnosed HIV-1-infected individuals.

Rationale: The paper specifically states that only the integrase region of the pol gene was sequenced, not the entire pol gene. The study focused exclusively on the integrase portion for drug resistance analysis.

Answer: No
"""

"""
Question: 2401

Evidence: Forty-two volunteers recently diagnosed as HIV-1 positive between January 2021 and January 2022 were selected for this study conducted in Porto Alegre, RS, South Brazil.

Rationale: The paper clearly states that all samples were from Porto Alegre, Rio Grande do Sul state, in South Brazil. No sequences from other geographic regions are mentioned.

Answer: Porto Alegre, South Brazil
"""

"""
Question: 2402

Evidence: Forty-two volunteers recently diagnosed as HIV-1 positive between January 2021 and January 2022 were selected for this study conducted in Porto Alegre, RS, South Brazil.

Rationale: The paper explicitly states that samples were collected from individuals diagnosed between January 2021 and January 2022, providing the specific time period for sample collection.

Answer: January 2021 to January 2022
"""

"""
Question: 2502

Evidence: DNA sequencing was performed at ACTGene Laboratory (Alvorada, Brazil) using an ABI-PRISM 3100 Genetic Analyzer automated sequencer armed with 50 cm capillaries and POP6 polymer (Applied Biosystems).

Rationale: The paper describes using an ABI-PRISM 3100 Genetic Analyzer, which is a Sanger sequencing platform. This confirms that Sanger sequencing was the method used, and no next-generation sequencing technologies are mentioned.

Answer: Yes
"""

"""
Question: 2503

Evidence: DNA sequencing was performed at ACTGene Laboratory (Alvorada, Brazil) using an ABI-PRISM 3100 Genetic Analyzer automated sequencer armed with 50 cm capillaries and POP6 polymer (Applied Biosystems).

Rationale: The paper specifically mentions using an ABI-PRISM 3100 Genetic Analyzer, which is a Sanger sequencing platform. No references to next-generation sequencing (NGS) technologies are made anywhere in the text.

Answer: No
"""

"""
Question: 2504

Evidence: The paper does not mention any cloning procedures. The methods describe direct RT-PCR amplification and sequencing of viral RNA without cloning steps.

Rationale: After thorough review of the methods section, no cloning procedures are described. The sequencing was performed directly on PCR products without molecular cloning.

Answer: No
"""

"""
Question: 2505

Evidence: The paper does not mention single genome sequencing. The methods describe standard RT-PCR amplification and sequencing approaches.

Rationale: No reference to single genome sequencing is made in the paper. The sequencing methodology described does not indicate that single genome amplification was performed.

Answer: No
"""

"""
Question: 2506

Evidence: The paper does not mention molecular cloning. The methods describe direct amplification and sequencing of viral RNA.

Rationale: After careful review of the methods section, no molecular cloning procedures are described. The sequencing was performed on bulk PCR products without cloning steps.

Answer: No
"""

"""
Question: 2601

Evidence: Plasma samples were collected from the 42 patients and stored at −80°C until analysis. Total RNA was extracted using MagMAX ^™^ CORE Nucleic Acid Purification Kit.

Rationale: The paper explicitly states that plasma samples were collected from all 42 patients and that viral RNA was extracted from these plasma samples for sequencing, confirming plasma virus sequencing was performed.

Answer: Yes
"""

"""
Question: 2602

Evidence: The paper does not mention PBMC sampling or sequencing. Only plasma samples are described as the source for viral RNA extraction.

Rationale: After thorough review of the methods section, only plasma samples are mentioned as the source material. No references to PBMC isolation, DNA extraction, or proviral sequencing are made.

Answer: No
"""

"""
Question: 2603

Evidence: Plasma samples were collected from the 42 patients and stored at −80°C until analysis. Total RNA was extracted using MagMAX ^™^ CORE Nucleic Acid Purification Kit.

Rationale: The paper states that plasma samples were collected from all 42 patients and that viral RNA was extracted from these plasma samples, indicating all 42 samples underwent plasma virus sequencing.

Answer: 42
"""

"""
Question: 2604

Evidence: The paper does not mention PBMC sampling or sequencing. Only plasma samples are described as the source for viral RNA extraction.

Rationale: No PBMC sampling or sequencing is mentioned in the paper. Only plasma-based RNA sequencing is described for all 42 patients.

Answer: 0
"""

"""
Question: 2605

Evidence: For all patients included, initial viral load and CD4+ T lymphocyte counts were analysed. Viral load (copies/mL) 17 180 (7567–57 024).

Rationale: The paper reports viral load measurements for all patients (median 17,180 copies/mL), indicating active HIV replication was present in the individuals from whom sequences were obtained.

Answer: Yes
"""

"""
Question: 2606

Evidence: Plasma samples were collected from the 42 patients and stored at −80°C until analysis. Total RNA was extracted using MagMAX ^™^ CORE Nucleic Acid Purification Kit.

Rationale: The paper explicitly states that sequencing was performed on viral RNA extracted from plasma samples, not from proviral DNA from PBMCs. This indicates sequences were from replicating virus, not the proviral reservoir.

Answer: No
"""

"""
Question: 2701

Evidence: The individuals were at least 18 years old at the time of recruitment and ART naive. Age (years) 32 (24–40).

Rationale: The paper specifies that all individuals were at least 18 years old, with a median age of 32 years. No infants or children were included in the study population.

Answer: No
"""

"""
Question: 2702

Evidence: The paper does not mention any clinical trials. The study describes a observational cohort of newly diagnosed individuals.

Rationale: After thorough review of the paper, no references to clinical trials are made. The study appears to be an observational analysis of recently diagnosed individuals, not part of a clinical trial.

Answer: No
"""

"""
Question: 2703

Evidence: The paper does not mention any clinical trials. The study describes a observational cohort of newly diagnosed individuals.

Rationale: Since no clinical trials are mentioned in the paper, it can be concluded that none of the individuals were in a clinical trial.

Answer: No
"""

"""
Question: 3101

Evidence: Forty-two volunteers recently diagnosed as HIV-1 positive between January 2021 and January 2022 were selected for this study. Plasma samples were collected from the 42 patients.

Rationale: The paper clearly states that 42 individuals were included in the study and that samples were obtained from all 42 for HIV sequencing.

Answer: 42
"""

"""
Question: 3102

Evidence: Plasma samples were collected from the 42 patients and stored at −80°C until analysis. Total RNA was extracted using MagMAX ^™^ CORE Nucleic Acid Purification Kit.

Rationale: The paper indicates that all 42 individuals provided plasma samples that underwent RNA extraction and subsequent sequencing, confirming that all individuals in the study underwent HIV sequencing.

Answer: Yes
"""

"""
Question: 4101

Evidence: Forty-two volunteers recently diagnosed as HIV-1 positive between January 2021 and January 2022 were selected for this study. The patients were selected based on new diagnoses and the individuals were ART naive.

Rationale: The paper explicitly states that all 42 individuals were ART-naive at the time of sampling, confirming that HIV sequences were obtained exclusively from ART-naive individuals.

Answer: Yes
"""

"""
Question: 4102

Evidence: The individuals were at least 18 years old at the time of recruitment and ART naive. None of the volunteers used ARV pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) 90 days preceding the sampling.

Rationale: The paper clearly states that all individuals were ART-naive and had not used PrEP or PEP in the 90 days preceding sampling, indicating no ART-experienced individuals were included.

Answer: No
"""

"""
Question: 4103

Evidence: The individuals were at least 18 years old at the time of recruitment and ART naive. None of the volunteers used ARV pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) 90 days preceding the sampling.

Rationale: The paper specifies that all 42 individuals were ART-naive, with no mention of ART-experienced individuals. Therefore, sequences only come from ART-naive persons.

Answer: No
"""

"""
Question: 4104

Evidence: Forty-two volunteers recently diagnosed as HIV-1 positive between January 2021 and January 2022 were selected for this study. The individuals were ART naive.

Rationale: The paper explicitly states that all 42 individuals included in the study were ART-naive at the time of sampling.

Answer: 42
"""

"""
Question: 4105

Evidence: The individuals were at least 18 years old at the time of recruitment and ART naive. None of the volunteers used ARV pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) 90 days preceding the sampling.

Rationale: The paper provides clear information that all individuals were ART-naive and had not used PrEP/PEP recently, providing complete ART history information for the study population.

Answer: Yes
"""

"""
Question: 4201

Evidence: Viral strains carrying TDRMs against INSTIs were not detected in the present study. Transmitted drug resistance mutations (TDRMs) are associated with ineffective ART, and have been reported in Brazil and worldwide.

Rationale: The paper explicitly evaluates and reports on transmitted drug resistance (TDR) against INSTIs, stating that no TDRMs were detected in the study population.

Answer: Yes
"""

"""
Question: 4202

Evidence: Viral strains carrying TDRMs against INSTIs were not detected in the present study. All the volunteers were susceptible to INSTIs when submitted to the Stanford University HIV Drug Resistance Database algorithm.

Rationale: The paper evaluates pretreatment drug resistance in ART-naive individuals and reports the prevalence (0%) of transmitted drug resistance mutations against INSTIs in this population.

Answer: Yes
"""

"""
Question: 4301

Evidence: The individuals were at least 18 years old at the time of recruitment and ART naive. None of the volunteers used ARV pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) 90 days preceding the sampling.

Rationale: The paper clearly states that all individuals were ART-naive and had not received any antiretroviral drugs, including PrEP or PEP, in the 90 days preceding sampling.

Answer: None
"""

"""
Question: 4302

Evidence: The individuals were at least 18 years old at the time of recruitment and ART naive. None of the volunteers used ARV pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) 90 days preceding the sampling.

Rationale: Since all individuals were ART-naive and had not received PrEP/PEP, no individuals in the study received integrase inhibitors or any other antiretroviral drugs.

Answer: No
"""

"""
Question: 4303

Evidence: The individuals were at least 18 years old at the time of recruitment and ART naive. None of the volunteers used ARV pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) 90 days preceding the sampling.

Rationale: The paper explicitly states that all individuals were ART-naive, meaning no one had received protease inhibitors or any other antiretroviral drugs.

Answer: No
"""

"""
Question: 4304

Evidence: The individuals were at least 18 years old at the time of recruitment and ART naive. None of the volunteers used ARV pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) 90 days preceding the sampling.

Rationale: Since all individuals were ART-naive, none received any ART regimen, making the question about receiving the same ART not applicable as no ART was received.

Answer: Yes
"""

"""
Question: 4305

Evidence: The individuals were at least 18 years old at the time of recruitment and ART naive. None of the volunteers used ARV pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) 90 days preceding the sampling.

Rationale: The paper explicitly states that all individuals were ART-naive, meaning they had not received any integrase strand transfer inhibitors (INSTIs) or other antiretroviral drugs.

Answer: Yes
"""

"""
Question: 4403

Evidence: The individuals were at least 18 years old at the time of recruitment and ART naive. None of the volunteers used ARV pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) 90 days preceding the sampling.

Rationale: Since all individuals were ART-naive, no one received any ART regimens, including multiple regimens.

Answer: 0
"""

"""
Question: 4404

Evidence: The individuals were at least 18 years old at the time of recruitment and ART naive. None of the volunteers used ARV pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) 90 days preceding the sampling.

Rationale: The paper explicitly states that all individuals were ART-naive, meaning no one received any ART regimens, including more than two regimens.

Answer: 0
"""

"""
Question: 4405

Evidence: The individuals were at least 18"""
Question: 4405

Evidence: The individuals were at least 18 years old at the time of recruitment and ART naive. None of the volunteers used ARV pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) 90 days preceding the sampling.

Rationale: Since all individuals were ART-naive, they all received the same number of ART regimens, which is zero.

Answer: Yes
"""

"""
Question: 4406

Evidence: The individuals were at least 18 years old at the time of recruitment and ART naive. None of the volunteers used ARV pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) 90 days preceding the sampling.

Rationale: The paper explicitly states that all individuals were ART-naive, meaning no one received any ART regimens at all.

Answer: Yes
"""

"""
Question: 4501

Evidence: The individuals were at least 18 years old at the time of recruitment and ART naive. None of the volunteers used ARV pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) 90 days preceding the sampling.

Rationale: Since all individuals were ART-naive, no one received dolutegravir or any other antiretroviral drugs.

Answer: 0
"""

"""
Question: 4502

Evidence: The individuals were at least 18 years old at the time of recruitment and ART naive. None of the volunteers used ARV pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) 90 days preceding the sampling.

Rationale: The paper explicitly states that all individuals were ART-naive, meaning no one received darunavir or any other antiretroviral drugs.

Answer: 0
"""

"""
Question: 5101

Evidence: Viral strains carrying TDRMs against INSTIs were not detected in the present study. All the volunteers were susceptible to INSTIs when submitted to the Stanford University HIV Drug Resistance Database algorithm.

Rationale: The paper explicitly states that no transmitted drug resistance mutations (TDRMs) against INSTIs were detected in any of the 42 individuals studied.

Answer: 0
"""

"""
Question: 5102

Evidence: Viral strains carrying TDRMs against INSTIs were not detected in the present study. Moreover, none of the 42 individuals presented major mutations against raltegravir, dolutegravir, elvitegravir, bictegravir or cabotegravir.

Rationale: The paper clearly states that no major INSTI-resistance mutations were found in any of the 42 ART-naive individuals studied.

Answer: 0
"""

"""
Question: 5103

Evidence: The paper does not mention TDF (tenofovir disoproxil fumarate) resistance mutations. The study focused exclusively on integrase strand transfer inhibitors (INSTIs) and sequenced only the integrase gene.

Rationale: The paper specifically studied resistance to INSTIs and only sequenced the integrase gene. No analysis of NRTI resistance, including TDF resistance, was performed or reported.

Answer: NA
"""

"""
Question: 5104

Evidence: Viral strains carrying TDRMs against INSTIs were not detected in the present study. Moreover, none of the 42 individuals presented major mutations against raltegravir, dolutegravir, elvitegravir, bictegravir or cabotegravir.

Rationale: The paper explicitly states that no major INSTI-resistance mutations were detected in any of the individuals studied. Only accessory polymorphisms L74M and L74I were observed, but these are not considered major resistance mutations.

Answer: None
"""

"""
Question: 6101

Evidence: The TDRM analysis was performed using the Stanford University HIV Drug Resistance Database algorithm. All the volunteers were susceptible to INSTIs when submitted to the Stanford University HIV Drug Resistance Database algorithm.

Rationale: The paper used genotypic resistance testing through the Stanford HIV Drug Resistance Database algorithm, not phenotypic susceptibility testing. No phenotypic susceptibility tests were performed.

Answer: NA
"""

"""
Question: 6102

Evidence: The paper does not mention any IC50 or IC90 values. The resistance analysis was performed using genotypic methods through the Stanford HIV Drug Resistance Database.

Rationale: After thorough review of the paper, no IC50 or IC90 values are reported. The study used genotypic resistance analysis rather than phenotypic susceptibility testing.

Answer: No
"""

"""
Question: 6103

Evidence: The paper does not mention any IC50 fold change values. The resistance analysis was performed using genotypic methods through the Stanford HIV Drug Resistance Database.

Rationale: No IC50 fold change values are reported in the paper. The study relied on genotypic resistance interpretation rather than phenotypic susceptibility measurements.

Answer: No
"""

"""
Question: 6104

Evidence: The TDRM analysis was performed using the Stanford University HIV Drug Resistance Database algorithm. All the volunteers were susceptible to INSTIs when submitted to the Stanford University HIV Drug Resistance Database algorithm.

Rationale: The paper used the Stanford University HIV Drug Resistance Database algorithm for genotypic resistance interpretation. No phenotypic susceptibility assays were performed.

Answer: NA
"""

"""
Question: 6105

Evidence: The paper does not mention replication capacity testing. The study focused on genetic diversity and drug resistance mutation analysis through sequencing.

Rationale: After thorough review of the paper, no replication capacity data are reported. The study focused on sequencing and genotypic resistance analysis only.

Answer: No
"""

"""
Question: 6106

Evidence: The TDRM analysis was performed using the Stanford University HIV Drug Resistance Database algorithm. Moreover, none of the 42 individuals presented major mutations against raltegravir, dolutegravir, elvitegravir, bictegravir or cabotegravir.

Rationale: While the paper mentions susceptibility to several INSTI drugs (raltegravir, dolutegravir, elvitegravir, bictegravir, cabotegravir) in the context of genotypic resistance analysis, no actual phenotypic susceptibility testing was performed on any drugs.

Answer: NA
"""

"""
Question: 7101

Evidence: The paper does not mention site-directed mutagenesis. The study analyzed viral sequences from clinical samples of ART-naive individuals.

Rationale: After thorough review of the paper, no site-directed mutations or engineered isolates are mentioned. All sequences were obtained from natural infections in clinical samples.

Answer: No
"""

"""
Question: 7102

Evidence: The paper does not mention any in vitro passage experiments. The study focuses on sequencing viral samples from ART-naive individuals and analyzing genetic diversity and drug resistance mutations.

Rationale: No in vitro passage experiments are described in the paper. The research methodology involves sequencing clinical samples from patients, not laboratory passage experiments.

Answer: No
"""